Professional Documents
Culture Documents
Epinephrine (Adrenaline)
Mechanism of Action
- and -adrenergic activity
Indication(s)
VF / pulseless VT unresponsive to defibrillation
ACLS Class IIb Recommendation ACLS Class Indeterminate Recommendation
Epinephrine (Adrenaline)
Standard dose = 1 mg every 3-5 minutes
Follow each dose with saline flush May be given via ET tube (double the dose)
Epinephrine (Adrenaline)
Precautions
Tachycardia, Hypertension, Pulmonary edema Myocardial Ischemia, Angina
Increased myocardial oxygen demand
Misc
Provided as 1:10,000 prefilled syringe 10 mL = 1 mg Also available as 1:1,000 vial (more concentrated) 1 mL = 1 mg
Epinephrine Drip
Initiate at 1 mcg/min, titrate to hemodynamic endpoint (2-10 mcg/min)
Vasopressin
Mechanism of Action
Naturally occurring antidiuretic hormone Acts as non-adrenergic peripheral vasoconstrictor Direct stimulation of smooth muscle V1 receptors Does not increase myocardial O2 consumption
No beta effects
Vasopressin
Indication(s)
VF / pulseless VT unresponsive to defibrillation
ACLS Class IIb Recommendation ACLS Class Indeterminate Recommendation
Asystole / PEA Vasodilatory shock (i.e. septic shock) May be helpful in prolonged arrest
Longer half-life than epinephrine
Vasopressin
Dose is 40 units IV x1 dose
alternative to 1st or 2nd dose of epinephrine
Vasopressin
Precautions
Hypertension, Tremor Myocardial Ischemia, Angina
Increased peripheral vascular resistance
Misc
Provided as 20 unit/mL ampule
Atropine
Mechanism of Action
Enhances sinus node automaticity & AV conduction Parasympatholytic (direct vagolytic action)
Atropine
Symptomatic Bradycardia: 0.5 mg IV
Doses less than 0.5 mg may cause paradoxical bradycardia Do not delay pacing for symptomatic patients
Indication(s)
Symptomatic bradycardia
ACLS Class I Recommendation ACLS Class IIa Recommendation ACLS Class IIb Recommendation ACLS Class Indeterminate Recommendation
Atropine
Precautions
Existing tachycardia Avoid in hypothermic bradycardia Increases myocardial O2 demand
Classification of VF/VT
Persistent (shock resistant): persists after multiple shocks Refractory: persists after shocks, CPR, airway, AND drugs Recurrent: returns after a successful intervention
Misc
May be used for organophosphate poisoning (i.e. nerve agent)
Extremely large doses may be needed in this case (2-4 mg or higher with exposure to nerve agents)
Amiodarone (Cordarone)
Mechanism of Action
Delays repolarization (prolongs refractory period) Blocks - and -adrenergic receptors Affects sodium, potassium, and calcium channels
Amiodarone (Cordarone)
Cardiac Arrest (VF/pulseless VT) given as 300 mg rapid IV infusion in 20-30 mL D5W
One supplemental dose of 150 mg may be given in 3-5 min if refractory VF/pulseless VT
Indication(s)
Persistent or recurrent VF / pulseless VT
ACLS Class IIb Recommendation
VT (with pulse), dose is 150 mg IV every 10 min as needed Continuous Infusion (max of 2.2 grams/24 hr)
900 mg in 500 mL D5W (1.8 mg/mL) 1 mg/min (33.3 mL/hr) for 6 hr, then 0.5 mg/min (16.6 mL/hr) for remainder of infusion
Amiodarone (Cordarone)
Precautions
Hypotension, dizziness, fatigue, N/V Significant bradycardia & heart block Pulmonary & hepatic toxicities
Lidocaine
Mechanism of Action
Depresses diastolic depolarization & automaticity in the ventricles
Indication(s)
Persistent or recurrent VF / pulseless VT
ACLS Class Indeterminate Recommendation Most useful in sustained VF / pulseless VT or wide-complex tachycardia of unknown origin
Misc
Provided as 150 mg ampule Multiple drug interactions Should be administered via central line if possible Infusions > 2 hr must be in glass or PVC-free
Perfusing arrhythmias
Lidocaine
Cardiac Arrest (VF/pulseless VT) given as 1 1.5 mg/kg IV initially
Repeat doses of 0.5 0.75 mg/kg ( of initial dose) IV every 5-10 min for a total of 3 doses (or) 3 mg/kg May give via ET tube (double the dose)
Lidocaine
Precautions
Bradycardia, hypotension, heart block, sinus node depression, N/V, double vision, dyspnea Excessive drowsiness is a sign of high blood levels leading to seizures, loss of consciousness, coma
Stop infusion immediately, draw levels
Lidocaine Drip
Start at 1-4 mg/min to achieve levels of 1.5 6 mcg/mL Reduce maintenance infusion if hepatic impairment Constant ECG monitoring is necessary w/ infusions
Procainamide (Pronestyl)
Mechanism of Action
Depresses the excitability of cardiac muscle to electrical stimulation and slows conduction in the atrium, the bundle of HIS and the ventricle
Procainamide (Pronestyl)
PVCs and Recurrent VT: 20 mg/min
Titrate to suppression of arrhythmia 17 mg/kg max (or) limited by adverse events (i.e.) hypotension, QRS widened by 50% Follow with 1-4 mg/min drip
Indication(s)
Recurrent VF / pulseless VT
ACLS Class Indeterminate Recommendation Most appropriate if return of circulation at least twice & has perfusing rhythm
Precautions
May precipitate or exacerbate CHF Correct hypokalemia before use Can further depress AV conduction in digoxin-induced toxicity Hypotension, rash, and diarrhea are major side effects
Other Antiarrhythmics
(Not on Exam)
Magnesium Sulfate
Indication(s):
Torsades de pointes
ACLS Class IIb Recommendation if known or suspected hypomagnesaemia (chronic malnutrition, etc.)
Sodium Bicarbonate
Indication(s)
Hyperkalemia
ACLS Class I Recommendation ACLS Class IIa Recommendation
Calcium Chloride
Hypercalcaemia & Cardiac resuscitation
Hyperkalemia & Ca++Channel Blocker Overdose
0.5-1 gram IV (~5-10 mL of 10% solution)
Precautions
Do not routinely use in cardiac arrest Do not mix with sodium bicarbonate Flush line after infusion to prevent precipitation May cause a decrease in HR or BP Questionable value unless documented hypocalcaemia
Vasopressors
Is the tank full?
Without enough fluid in the system, the blood pressure will not correct
Dopamine (Intropin)
Mechanism of Action
-, -, and DA receptor agonist
Indication(s)
Refractory symptomatic bradycardia Failed atropine & pacing (or while awaiting pacing)
Norepinephrine (Levophed)
Mechanism of Action
Powerful -receptors agonist (arterial/venous) 1-receptor agonist ( myocardial contractions)
Dobutamine (Dobutrex)
Mechanism of Action
Primarily affects -receptors
Indication(s)
Severe & hemodynamically significant hypotension plus low total peripheral vascular resistance
Indication(s)
Severe systolic heart failure and cannot tolerate vasopressors Treatment of choice if hemodynamically significant right-ventricular infarction
Adenosine (Adenocard)
Mechanism of Action
Slows conduction through AV node Interrupts AV nodal reentry pathways
Adenosine (Adenocard)
Diagnostic
Undefined, stable narrow-complex SVT Will not convert atrial tachycardias or VT as reentry not involving the AV or sinus node
Indication(s)
Defined, stable, narrow-complex AV or sinus nodal reentry tachycardia (reentry SVT)
ACLS Class I Recommendation ACLS Class IIb Recommendation
6 mg rapid IV push (over 1-3 seconds) followed by immediate saline flush push
May repeat with 12 mg bolus (x1-2) if no conversion
Adenosine (Adenocard)
Precautions
Transient bradycardia (asystole!), ventricular ectopy, flushing, dyspnea, and chest pain Caution in patients prone to bradycardia or conduction defects without pacemaker
Beta Blockers
Mechanism of Action
Block beta-adrenergic receptors
Beta Blockers
Precautions
Expert consultation needed with Wolff-ParkinsonWhite syndrome Causes hypotension, difficulty breathing, severe bradycardia Contraindicated in patients with asthma or reactive airway disease Overdose management
Fluids are most useful for hypotension Repeated epinephrine, glucagon may help with BP/HR
Milrinone (Primacor)
Mechanism of Action
Phosphodiesterase III inhibitor vasodilator
Indication(s)
Severe CHF or Refractory cardiogenic shock
Ideal because increases cardiac output without increasing myocardial oxygen demand
50 mcg/kg load over 10 min, then 0.375 0.75 mcg/kg/min maintenance infusion Precautions
Increased heart rate, ventricular irritability, sulfa allergy
Digoxin (Lanoxin)
Mechanism of Action
Cardiac Glycoside Slows ventricular response
Indication(s)
Atrial fibrillation / flutter PSVT
Oxygen: 100%
Assist with myocardial oxygen demands
10 15 mcg/kg load
Negative chronotropic effects
Initially seen at 5-30 min Peak effect at 1.5-3 hr
Nitroglycerin
Mechanism of Action
Reduces cardiac oxygen demand by decreasing left ventricular pressure and systemic vascular resistance Dilates coronary arteries and improves collateral flow to ischemic regions
Nitroglycerin
Precautions
Hypotensive patients RV infarction ED treatment Causes hypotension, syncope, headache, nausea, tachycardia & paradoxical bradycardia, hypoxemia
Indication(s)
Stable Angina: 0.4 mg tablet every 5 min x3 Unstable Angina (& other ACS): 12.5 25 mcg IV bolus followed by 10-20 mcg/min continuous infusion (titrate to effect)
Nitroprusside (Nipride)
Mechanism of Action
Potent, rapid-acting vasodilator that reduces both preload and afterload
Nitroprusside (Nipride)
Precautions
Monitor closely in elderly & hypovolemic patients Hypotension, CO2 retention, headache, nausea, abdominal cramping
Indications
Hypertensive Emergencies Acute Pulmonary Edema & Heart Failure
Initiate at 0.1 mcg/kg/min, titrate every 3-5 min to 5 mcg/kg/min (max of 10 mcg/kg/min)
Be sure to protect bag from light!
Fibrinolytics
Absolute Contraindications
Any prior intracranial hemorrhage Known structural cerebral vascular lesion (i.e. AVM) Known malignant intracranial neoplasm Ischemic stroke within 3 months (except acute ischemic stroke within 3 hours) Suspected aortic dissection Active bleeding or bleeding diathesis (except menses) Significant closed head/facial trauma within 3 months
Fibrinolytics
Relative Contraindications
Hx of chronic, severe, poorly controlled HTN Hx prior ischemic stroke >3 months, dementia, or other intracranial pathology Traumatic or prolonged CPR or major surg (<3 wks) Recent internal bleeding (within 2-4 weeks) Noncompressible vascular punctures Pregnancy Active Peptic Ulcer Disease Allergy on prior exposure to fibrinolytic Current use of anticoagulants (higher dose = higher risk)
tPA
Indication(s)
Acute, ischemic stroke
Total Dose: 0.9 mg/kg (max of 90 mg) Give 10% of total dose as initial IV bolus over 1 minute Give remaining 90% as IV infusion over 60 minutes
tPA
Precautions
Do not use if neurological signs are spontaneously clearing and are near baseline Physician should discuss risks/benefits with patient Check against absolute & relative contraindications for fibrinolytic therapy
Indication
ACS without ST-segment elevation
Precautions
Active/Recent hx of abnormal bleeding, CVA within 30 days, Severe hypertension (SBP >200, DBP >110), Thrombocytopenia, SCr Bleeding, hypotension, GI hemorrhage, pulmonary hemorrhage
Eptifibatide (Integrilin)
180 mcg/kg bolus, then 2 mcg/kg/min Platelet function recovers in 4 to 8 hours
Tirofiban (Aggrastat)
0.4 mcg/kg/min bolus (over 30 min), then 0.1 mcg/kg/min infusion for 48-96 hr Platelet function recovers in 4 to 8 hours
Heparin (unfractionated)
Mechanism
Inactivates thrombin & activated coagulation factors IX, X, XI, XII
Indication(s)
Adjuvant therapy in AMI (STEMI & NSTEMI)
Indication(s)
Adjuvant therapy in AMI (STEMI & NSTEMI)
60 unit/kg load (max of 4,000 units) 12 units/kg/hr infusion (max of 1,000 units/hr)
Keep aPTT in target range of 1.5 2x control for 48 hours (or) until after angioplasty Follow institutional protocol Begin with fibrin-specific lytics (alteplase, etc.)
STEMI
As adjunct with fibrinolytic
In patients, ages <75 yr with SCr <2.5 in males, <2 in females
Clopidogrel (Plavix)
Mechanism of Action
Irreversibly inhibits platelet adenosine diphosphate receptor resulting in reduction of platelet aggregation
Medication Overdose
Naloxone (Narcan)
Reverses opiate activities, including respiratory depression from natural & synthetic opioids 0.4 2 mg every 2-3 min up to 10 mg Duration of 20-60 min, typically shorter than most opioids so will need repeat doses May be given via the ET tube (double the dose)
Flumazenil (Romazicon)
Reverses sedative effects of benzodiazepines Does not reverse respiratory depression with BZD 0.2 mg over 15 sec, repeat in 1 min intervals up to 1 mg Duration of ~60 minutes, repeat as needed
Current Guidelines
Circulation, Volume 112, Issue 24 Supplement; December 13, 2005
Freely available at http://circ.ahajournals.org
Handbook of Emergency Cardiovascular Care. American Heart Association, Guidelines CPR/ECC 2005.
Available for purchase through AHA
10